535. Risk Factors for Seeking Medical Care Following Monoclonal Antibody Treatment For COVID-19

BACKGROUND: The FDA issued emergency use authorization for neutralizing monoclonal antibodies (mAb) for the treatment of mild-moderate coronavirus disease 2019 (COVID-19) in patients who were at high risk of disease progression. METHODS: In this case-control study, we assessed risk factors for patie...

Descripción completa

Detalles Bibliográficos
Autores principales: MALIK, I S M A I L O, Szpunar, Susan M, Salaytah, Natali, Bhargava, Ashish, Sharma, Mamta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679425/
http://dx.doi.org/10.1093/ofid/ofad500.604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679425/
http://dx.doi.org/10.1093/ofid/ofad500.604

Ejemplares similares